| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ifosfamide | CTRPv2 | pan-cancer | AAC | 0.25 | 2e-06 |
| mRNA | lapatinib | GDSC1000 | pan-cancer | AAC | 0.24 | 2e-06 |
| mRNA | lapatinib | gCSI | pan-cancer | AAC | 0.26 | 6e-06 |
| mRNA | DMOG | GDSC1000 | pan-cancer | AAC | 0.15 | 8e-06 |
| mRNA | VAF-347 | CTRPv2 | pan-cancer | AAC | 0.2 | 2e-05 |
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | 0.22 | 2e-05 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.24 | 7e-05 |
| mRNA | 17-AAG | GDSC1000 | pan-cancer | AAC | 0.13 | 0.0001 |
| mRNA | NVP-BEZ235 | GDSC1000 | pan-cancer | AAC | 0.14 | 0.0001 |
| mRNA | BRD-A02303741:carboplatin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.14 | 0.0001 |